Versican and the regulation of cell phenotype in disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background Versican is an extracellular matrix (ECM) proteoglycan that is present in the pericellular environment of most tissues and increases in many different diseases. Versican interacts with cells to influence the ability of cells to proliferate, migrate, adhere and assemble an ECM. Scope of Review The structure of the versican molecule is briefly reviewed and studies highlighting those factors that promote versican synthesis and degradation and their impact on cell phenotype in disease are discussed. Particular attention is given to vascular disease, but other diseases where versican is important are covered as well, most notably different forms of cancers. Attention is given to mechanisms(s) by which versican influences cell behaviors through either direct or indirect processes. Versican produced by either stromal cells or myeloid cells can have a major impact influencing immunity and inflammation. Finally, studies controlling versican accumulation that either delay or inhibit the progression of disease will be highlighted. Major Conclusions Versican is one component of the ECM that can influence the ability of cells to proliferate, migrate, adhere, and remodel the ECM. Targeting versican as a way to control cell phenotype offers a novel approach in the treatment of disease. Significance ECM molecules such as versican contribute to the structural integrity of tissues and interact with cells through direct and indirect means to regulate, in part, cellular events that form the basis of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chondroitinase ABC promotes functional recovery after spinal cord injury
Bradbury, E. J., Moon, L. D. F., Popat, R. J., King, V. R., Bennett, G. S., Patel, P. N., Fawcett, J. W., & McMahon, S. B. (2002) · Nature · doi:10.1038/416636a · Cited by 2,357 · cited 1×
“The importance of the hyalectins in preventing nerve regeneration is further highlighted by studies that show that degradation of CS chains by chondroitinase ABC lyase treatment following spinal cord injury in experimental animals promotes regeneration of both ascending and descending corticospinal-tract axons [126].”
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L., & Karin, M. (2009) · Nature · doi:10.1038/nature07623 · Cited by 1,100
Extracellular matrix of the central nervous system: from neglect to challenge
Zimmermann, D. R., & Dours-Zimmermann, M. T. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0485-9 · Cited by 465 · cited 4×
“The V2 isoform is mostly found in the central nervous system (CNS) [60], but has been found in other tissues as well.”
InfluentialGrowth factor binding to the pericellular matrix and its importance in tissue engineering☆
MACRI, L., SILVERSTEIN, D., & CLARK, R. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.015 · Cited by 292 · cited 1×
“Versican can also act as a reservoir for cytokines and growth factors to be released at various times, establishing fine control over cell activity and behavior [10,15,23,24].”
Kawashima, H., Atarashi, K., Hirose, M., Hirose, J., Yamada, S., Sugahara, K., & Miyasaka, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200396200 · Cited by 241
Milev, P., Maurel, P., Chiba, A., Mevissen, M., Popp, S., Yamaguchi, Y., Margolis, R. K., & Margolis, R. U. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8759 · Cited by 219
Brain derived versican V2 is a potent inhibitor of axonal growth
Schmalfeldt, M., Bandtlow, C. E., Dours-Zimmermann, M. T., Winterhalter, K. H., & Zimmermann, D. R. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.5.807 · Cited by 197
Structural Basis for Interactions between Tenascins and Lectican C-Type Lectin Domains
Lundell, A., Olin, A. I., Mörgelin, M., al-Karadaghi, S., Aspberg, A., & Logan, D. T. (2004) · Structure · doi:10.1016/j.str.2004.05.021 · Cited by 127
Miguel, R. F., Pollak, A., & Lubec, G. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.008 · Cited by 64 · cited 1×
“Furthermore, high levels of ADAMTS-1 in brain tissues are associated with neurodegenerative diseases such as Down syndrome, Alzheimer's, and Pick's disease [89].”
Cited by
Extracellular matrix structure
Theocharis, A. D., Skandalis, S. S., Gialeli, C., & Karamanos, N. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.001 · Cited by 2,598
“Versican regulates cell adhesion, migration and inflammation [40, 41].”
BackgroundProteoglycan form and function: A comprehensive nomenclature of proteoglycans
Iozzo, R. V., & Schaefer, L. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.02.003 · Cited by 1,263
C-type lectins in immunity and homeostasis
Brown, G. D., Willment, J. A., & Whitehead, L. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0004-8 · Cited by 744
Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis
Yahagi, K., Kolodgie, F. D., Otsuka, F., Finn, A. V., Davis, H. R., Joner, M., & Virmani, R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.164 · Cited by 548
Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics
Karamanos, N. K., Piperigkou, Z., Theocharis, A. D., Watanabe, H., Franchi, M., Baud, S., Brézillon, S., Götte, M., Passi, A., Vigetti, D., et al. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00354 · Cited by 367
Metadata
- Authors
- Wight, T. N., Kinsella, M. G., Evanko, S. P., Potter-Perigo, S., & Merrilees, M. J.
- Venue
- Biochimica et Biophysica Acta (BBA) - General Subjects
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 1840
- Issue
- 8
- Pages
- 2441-2451
- ISSN
- 0304-4165 (ISSN-L)
- OpenAlex
- W2021120177
- Cited by
- 128
- References
- 9
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Versican and the regulation of cell phenotype in disease. https://app.cochat.ai/papers/10.1016/j.bbagen.2013.12.028
- The paper
- Wight, T. N., Kinsella, M. G., Evanko, S. P., Potter-Perigo, S., & Merrilees, M. J. (2014). Versican and the regulation of cell phenotype in disease. Biochimica et Biophysica Acta (BBA) - General Subjects. https://doi.org/10.1016/j.bbagen.2013.12.028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.